BxPC-3: Evaluating Responses To Standard Therapeutic Agents In Subcutaneous Mouse Model Of Human Pancreatic Cancer

By Gunisha Arora, Medical and Scientific Writer, Scientific Development

Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, remains a devastating disease with late diagnoses, limited surgical options, high therapeutic resistance, and five-year survival rates below 10%. Addressing these challenges requires reliable preclinical models that can support the development of innovative therapies. The BxPC-3 human PDAC model has proven to be a valuable tool for both in vitro and in vivo evaluation of novel interventions, reflecting key genetic, molecular, and histological features of the disease.

Derived from a pancreatic adenocarcinoma patient, BxPC-3 tumors mirror the clinical complexity of PDAC, including TP53 mutation, loss of CDKN2A/p16 and SMAD4/DPC4, impaired TGFβ signaling, pro-angiogenic potential, fibrosis, and malignant necrosis. At Labcorp, we have conducted numerous studies using this model in NSG and NSG-dKO mice, consistently demonstrating reproducible tumor growth with long latency periods across agents, vehicles, and delivery modes.